158 related articles for article (PubMed ID: 19879061)
1. Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer.
D'Amico AV; Braccioforte MH; Moran BJ; Chen MH
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1329-37. PubMed ID: 19879061
[TBL] [Abstract][Full Text] [Related]
2. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):147-52. PubMed ID: 19744800
[TBL] [Abstract][Full Text] [Related]
3. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer.
Hoffman KE; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin MJ; Ross R; D'Amico AV
Cancer; 2010 Jun; 116(11):2590-5. PubMed ID: 20310055
[TBL] [Abstract][Full Text] [Related]
5. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
6. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
[TBL] [Abstract][Full Text] [Related]
7. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors.
Nguyen PL; Chen MH; Catalona WJ; Moul JW; Sun L; D'Amico AV
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):659-64. PubMed ID: 18692327
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors.
D'Amico AV; Chen MH; Catalona WJ; Sun L; Roehl KA; Moul JW
Cancer; 2007 Jul; 110(1):56-61. PubMed ID: 17530618
[TBL] [Abstract][Full Text] [Related]
9. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
Zhou P; Chen MH; McLeod D; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Oct; 23(28):6992-8. PubMed ID: 16192586
[TBL] [Abstract][Full Text] [Related]
10. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease.
D'Amico AV; Renshaw AA; Cote K; Hurwitz M; Beard C; Loffredo M; Chen MH
J Clin Oncol; 2004 Sep; 22(18):3726-32. PubMed ID: 15365069
[TBL] [Abstract][Full Text] [Related]
11. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.
D'Amico AV; Moul J; Carroll PR; Sun L; Lubeck D; Chen MH
J Clin Oncol; 2003 Jun; 21(11):2163-72. PubMed ID: 12775742
[TBL] [Abstract][Full Text] [Related]
12. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
13. Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study.
Abdollah F; Sun M; Schmitges J; Thuret R; Tian Z; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):95-103. PubMed ID: 22330991
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; D'Amico AV
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e209-15. PubMed ID: 23332383
[TBL] [Abstract][Full Text] [Related]
16. Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancer.
Kang J; Chen MH; Zhang Y; Moran BJ; Dosoretz DE; Katin MJ; Braccioforte MH; Salenius SA; D'Amico AV
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e463-7. PubMed ID: 21944463
[TBL] [Abstract][Full Text] [Related]
17. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
[TBL] [Abstract][Full Text] [Related]
18. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
D'Amico AV; Loffredo M; Renshaw AA; Loffredo B; Chen MH
J Clin Oncol; 2006 Sep; 24(25):4190-5. PubMed ID: 16943536
[TBL] [Abstract][Full Text] [Related]
19. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy.
Buyyounouski MK; Hanlon AL; Horwitz EM; Pollack A
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):59-66. PubMed ID: 17919840
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH
J Urol; 2003 Apr; 169(4):1320-4. PubMed ID: 12629352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]